BLACKLEDGER Selling Watch: CCJ, UEC, VKTX
BLACKLEDGER's latest selling watch update tracks CCJ, UEC, VKTX, NTLA, URG, SNDL from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Selling Watch Data
The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-09-12T08:00:40.694338+00:00.
- CCJ (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- UEC (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- VKTX (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- NTLA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- URG (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- SNDL (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- SUI (crypto): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- CRSP (stock): Bear public bias, Extended, public score 8.3/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
CCJ Public Research Bio
Name: Cameco Corporation. Market class: stock. Public bias: Bear. Public tier: Extended.
Cameco Corporation provides uranium for the generation of electricity in the Americas, Europe, and Asia. It operates in three segments: Uranium, Fuel Services, and Westinghouse. The Uranium segment engages in the exploration for, mining, milling, purchase, and sale of uranium concentrate. Its Fuel Services segment is involved in the refining, conve[redacted]on, and fabrication of uranium concentrate, as well as purchase and sale of conve[redacted]on services. The Westinghouse segment operates as a nuclear reactor technology original equipment manufacturer and a provider of products and services to commercial utilities and government agencies. It also provides outage and maintenance, engineering support, instrumentation and controls equipment, and plant modification services, as well as components and parts to nuclear reactors. The company sells its uranium and fuel products and services to nuclear utilities. Cameco Corporation was incor
- Latest public price/reference: $96.68
- Public market capitalization: $42.11B
- Recent public volume/reference: 2.09M
- One-month public movement: 11.92%
- Sector/category: Energy
Why CCJ Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Cameco (CCJ) Registers a Bigger Fall Than the Market: Important Facts to Note — Zacks
- Cameco vs. MP Materials: Which Crucial Renewable Energy Supplier Stock Is a Better Buy in 2026? — Motley Fool
- Cameco vs. TMC The Metals Co: Is a Uranium Stock or Rare Earth Metals Venture the Better Buy in 2026? — Motley Fool
- Energy Fuels Down 28% in the Past 6 Months: How to Play the Stock? — Zacks
UEC Public Research Bio
Name: Uranium Energy Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing of uranium and titanium concentrates properties in the United States, Canada, and the Republic of Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. The company was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
- Latest public price/reference: $10.45
- Public market capitalization: $5.17B
- Recent public volume/reference: 8.15M
- One-month public movement: 8.85%
- Sector/category: Energy
Why UEC Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Is Uranium Energy (UEC) a Buy as Wall Street Analysts Look Optimistic? — Zacks
- BWX Technologies Already Builds Reactors for the Navy. Why Is It Still the Cheapest Nuclear Stock? — Motley Fool
- Uranium Energy Rose as Jefferies Started Coverage — GuruFocus.com
- NuScale Advances Key Safety Component Toward SMR Commercialization — Zacks
VKTX Public Research Bio
Name: Viking Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystr
- Latest public price/reference: $31.98
- Public market capitalization: $3.73B
- Recent public volume/reference: 2.20M
- One-month public movement: 0.76%
- Sector/category: Healthcare
Why VKTX Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? — Zacks
- Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors — Zacks
- Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? — Motley Fool
- Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. — Motley Fool
NTLA Public Research Bio
Name: Intellia Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioed[redacted]. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeu
- Latest public price/reference: $11.74
- Public market capitalization: $1.65B
- Recent public volume/reference: 2.70M
- One-month public movement: 9.93%
- Sector/category: Healthcare
Why NTLA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? — Insider Monkey
- FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug — Zacks
- 3 Promising Genomics Stocks in the Spotlight in 2026 — Zacks
- Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform — Stocktwits
URG Public Research Bio
Name: Ur-Energy Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties in the United States. It holds interests in 12 projects located in the United States. The company's flagship property is the Lost Creek project covering an area of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 35,400 acres located in the Great Divide Basin, Wyoming. Ur-Energy Inc. was incorporated in 2004 and is headquartered in Littleton, Colorado.
- Latest public price/reference: $1.29
- Public market capitalization: $513.24M
- Recent public volume/reference: 5.20M
- One-month public movement: 5.74%
- Sector/category: Energy
Why URG Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Uranium Energy Stock Is Priced On Pounds It Has Not Sold Yet — Trefis
- From Yellowcake to Commercial Scale: Can Ur-Energy (URG) Live Up to Its Uranium Hype? — Insider Monkey
- Ur-Energy (URG) Q2 2026 Earnings Call Transcript — Motley Fool
- Ur-Energy Inc (URG) (Q2 2026) Earnings Call Highlights: Production Surges 47% as Shirley Basin ... — GuruFocus.com
SNDL Public Research Bio
Name: SNDL Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
SNDL Inc. engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada and internationally. It operates through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. The company engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sale of wines, beers, and spirits through liquor stores under the Wine and Beyond, Ace Liquor, and Liquor Depot retail banners; and private sale of adult-use cannabis products and accessories through its corporate-owned, controlled, and franchised retail cannabis stores. It also produces and distributes flower, pre-rolls, and vapes, as well as offers financial services; and provision of proprietary cannabis processing services. It offers its products under the Top Leaf, Contraband, Palmetto, Bon Jak, La Logue, Versus, Grasslands, Pearls by Grön, No Future, and Bhang Chocolate brands. The
- Latest public price/reference: $1.34
- Public market capitalization: $329.80M
- Recent public volume/reference: 2.02M
- One-month public movement: 8.94%
- Sector/category: Consumer Defensive
Why SNDL Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests – Quarterly Update Report — Exec Edge
- Weekly Roundup on the Cannabis Sector & Psychedelic Sector — Market Exclusive
- Should You Buy, Hold or Sell SNDL Stock Post Q4 Earnings Release? — Zacks
- SNDL Inc (SNDL) Q2 2026 Earnings Call Highlights: Strategic Moves Amid Market Challenges — GuruFocus.com
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.